Current and future targets of antiviral therapy in the hepatitis C virus life cycle

Nicholas S. Eyre, Karla J. Helbig, Michael R. Beard

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Advances in our understanding of the hepatitis C virus (HCV) life cycle have enabled the development of numerous clinically advanced direct-acting antivirals. Indeed, the recent approval of first-generation direct-acting antivirals that target the viral NS3-4A protease and NS5B RNA-dependent RNA polymerase brings closer the possibility of universally efficacious and well-tolerated antiviral therapies for this insidious infection. However, the complexities of comorbidities, unforeseen side effects or drug-drug interactions, viral diversity, the high mutation rate of HCV RNA replication and the elegant and constantly evolving mechanisms employed by HCV to evade host and therapeutically implemented antiviral strategies remain as significant obstacles to this goal. Here, we review advances in our understanding of the HCV life cycle and associated opportunities for antiviral therapy.

Original languageEnglish
Pages (from-to)947-965
Number of pages19
JournalFuture Virology
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 2014
Externally publishedYes

Keywords

  • Antiviral
  • Assembly
  • Egress
  • Entry
  • HCV
  • IFN
  • NS3-4A
  • NS5A
  • NS5B
  • Replication

Fingerprint Dive into the research topics of 'Current and future targets of antiviral therapy in the hepatitis C virus life cycle'. Together they form a unique fingerprint.

  • Cite this